Neurogenic pulmonary edema

WikiDoc Resources for Neurogenic pulmonary edema
Articles
Most recent articles on Neurogenic pulmonary edema Most cited articles on Neurogenic pulmonary edema Review articles on Neurogenic pulmonary edema Articles on Neurogenic pulmonary edema in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Neurogenic pulmonary edema Images of Neurogenic pulmonary edema Photos of Neurogenic pulmonary edema Podcasts & MP3s on Neurogenic pulmonary edema Videos on Neurogenic pulmonary edema
Evidence Based Medicine
Cochrane Collaboration on Neurogenic pulmonary edema Bandolier on Neurogenic pulmonary edema TRIP on Neurogenic pulmonary edema
Clinical Trials
Ongoing Trials on Neurogenic pulmonary edema at Clinical Trials.gov Trial results on Neurogenic pulmonary edema Clinical Trials on Neurogenic pulmonary edema at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Neurogenic pulmonary edema NICE Guidance on Neurogenic pulmonary edema NHS PRODIGY Guidance FDA on Neurogenic pulmonary edema CDC on Neurogenic pulmonary edema
Books
Books on Neurogenic pulmonary edema
News
Neurogenic pulmonary edema in the news Be alerted to news on Neurogenic pulmonary edema News trends on Neurogenic pulmonary edema
Commentary
Blogs on Neurogenic pulmonary edema
Definitions
Definitions of Neurogenic pulmonary edema
Patient Resources / Community
Patient resources on Neurogenic pulmonary edema Discussion groups on Neurogenic pulmonary edema Patient Handouts on Neurogenic pulmonary edema Directions to Hospitals Treating Neurogenic pulmonary edema Risk calculators and risk factors for Neurogenic pulmonary edema
Healthcare Provider Resources
Symptoms of Neurogenic pulmonary edema Causes & Risk Factors for Neurogenic pulmonary edema Diagnostic studies for Neurogenic pulmonary edema Treatment of Neurogenic pulmonary edema
Continuing Medical Education (CME)
CME Programs on Neurogenic pulmonary edema
International
Neurogenic pulmonary edema en Espanol Neurogenic pulmonary edema en Francais
Business
Neurogenic pulmonary edema in the Marketplace Patents on Neurogenic pulmonary edema
Experimental / Informatics
List of terms related to Neurogenic pulmonary edema

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• Pulmonary edema may develop in the setting of a sudden neurologic event. Neurogenic pulmonary edema usually appears within minutes to hours after cerebral injury.
• Neurogenic pulmonary edema is an acute life-threatening complication associated with many forms of central nervous system injury, such as:
  • Brain or spinal cord hemorrhage
  • Trauma
  • Tumors
  • Epilepsy
  • Infections
• The pathogenetic factors for the onset of neurogenic pulmonary edema include:
  • Increased intracranial pressure
  • Severe over-activation of the sympathetic nervous system
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Severe brain damage represents a risk factor for developing neurogenic pulmonary edema, which include:
  • Cerebral hemorrhage
  • Subarachnoid hemorrhage
  • Head injuries
  • Seizures

Natural History, Complications and Prognosis

• Misdiagnosis and inappropriate treatment may worsen cerebral damage because of hypoxemia or reduced cerebral perfusion pressure.
• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].